Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly ...

The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.

Hatim Husain, MD, discusses how the implementation of proactive prophylaxis strategies for patients taking amivantamab, ...

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

Yanghee Woo, MD, provides an overview of the CROSS trial which focused on treating patients with gastroesophageal junction ...

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the ...

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...

In an interview with Targeted Oncology, Michael Mauro, MD, delved into the rapidly advancing field of chronic myeloid ...

In this episode of Targeted Talks, Douglas Flora, MD, LSSBB, FACCC, discusses the transformative impact of artificial ...